Processingdeficient Progeroid Laminopathies — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for processingdeficient progeroid laminopathies. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
2
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Processingdeficient Progeroid Laminopathies

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sentynl Theraps Inc 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating processingdeficient progeroid laminopathies. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
29

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zokinvy
LONAFARNIB
 Sentynl Theraps Inc 2 68 — 2029-07-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7838531 Zokinvy method of use 68 2029-07-26
7838531 Zokinvy method of use 68 2029-07-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7838531 Zokinvy method of use 68 2029-07-26
7838531 Zokinvy method of use 68 2029-07-26

Related